Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease

Neurobiology of Disease

Volumn 67, Issue , 2014, Pages 191-202

  Gyoneva, Stefka ^a,b,c   Shapiro, Lauren ^b   Lazo, Carlos ^b   Garnier Amblard, Ethel ^b,d   Smith, Yoland ^a,b   Miller, Gary W ^a,b   Traynelis, Stephen F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d RFS Pharma LLC   (United States)

Author keywords

Acute brain slice; Imaging; Microglia; Neuroinflammation; Parkinson's disease; Preladenant

Indexed keywords

ADENOSINE A2A RECEPTOR; PRELADENANT; PURINERGIC P2Y12 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL MOTILITY; CHRONIC INFLAMMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG MECHANISM; MICROGLIA; MOUSE; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TISSUE INJURY; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; INTOXICATION; METABOLISM; SUBSTANTIA NIGRA;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; DISEASE MODELS, ANIMAL; INFLAMMATION; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICROGLIA; MPTP POISONING; SUBSTANTIA NIGRA;

EID: 84899848056     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.03.004     Document Type: Article

References (57)

1. Ascherio A., et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 2001, 50:56-63.
2. Avignone E., et al. Status epilepticus induces a particular microglial activation state characterized by enhanced purinergic signaling. J. Neurosci. 2008, 28:9133-9144.
3. Barcia C., et al. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 2004, 46:402-409.
4. 2A receptors. Exp. Neurol. 2011, 228:160-164.
5. Bernheimer H., et al. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
6. Block M.L., Hong J.-S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 2005, 76:77-98.
7. Block M.L., et al. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8:57-69.
8. 2A receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum. J. Comp. Neurol. 2012, 520:570-589.
9. Boison D., et al. Adenosine signaling and function in glial cells. Cell Death Differ. 2010, 17:1071-1082.
10. Carta A.R., et al. Inactivation of neuronal forebrain A2A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurochem. 2009, 111:1478-1489.
11. 2A adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 2001, 21:RC143.
12. Cunningham C. Microglia and NEURODEGENERATION: THE ROLE OF SYSTEMIC INFLAMMATION. Glia 2013, 61:71-90.
13. Davalos D., et al. ATP mediates rapid mecroglial response to local brain injury in vivo. Nat. Neurosci. 2005, 8:752-758.
14. Ferre S., et al. The striatopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci. 1993, 13:5402-5406.
15. Gagne J.J., Power M.C. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010, 74:995-1002.
16. Gao H.-M., Hong J.-S. Why neurodegenerative diseases are progressice: uncontrolled inflammation drives disease progression. Trends Immunol. 2008, 29:357-365.
17. Gao X., et al. Use of ibuprofen and risk of Parkinson disease. Neurology 2011, 76:863-869.
18. 11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 2006, 21:404-412.
19. Gyoneva S., Traynelis S.F. Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors. J. Biol. Chem. 2013, 288:15291-15302.
20. Hanisch U.-K. Microglia as a source and target of cytokines. Glia 2002, 40:140-155.
21. Hauser R.A., et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double blind, randomised trial. Lancet Neurol. 2011, 10:221-229.
22. 12 receptor regulates microglial activation by extracellular nucleotides. Nat. Neurosci. 2006, 9:1512-1519.
23. Hines D.J., et al. Microglia processes block the spread of damage in the brain and require functional chloride channels. Glia 2009, 57:1610-1618.
24. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2007, 2:141-151.
25. 3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 2000, 20:4106-4114.
26. Kanaan N.M., et al. Age and region-specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure in monkeys. Glia 2008, 56:1199-1214.
27. Kettenmann H., et al. Microglia: new roles for the synaptic stripper. Neuron 2013, 77:10-18.
28. Kish S.J., et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N. Engl. J. Med. 1988, 318:876-880.
29. Koizumi S., et al. Purinergic receptors in microglia: functional modal schifts of microglia mediated by P2 and P1 receptors. Glia 2013, 61:47-54.
30. Krabbe G., et al. Activation of serotonin receptors promotes microglial injury-induced motility but attenuates phagocytic activity. Brain Behav. Immun. 2012, 26:419-428.
31. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19:312-318.
32. Langston J., et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 1999, 46:598-605.
33. Lawson L., et al. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39:151-170.
34. Long-Smith C.M., et al. The influence of microglia on the pathogenesis of Parkinson's disease. Prog. Neurobiol. 2009, 89:277-287.
35. Mcgeer P., et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
36. Mcgeer P.L., et al. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol. 2003, 54:599-604.
37. Mogi M., et al. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci. Lett. 1994, 180:147-150.
38. Mogi M., et al. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 1994, 165:208-210.
39. Mogi M., et al. Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 1996, 211:13-16.
40. Morelli M., et al. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog. Brain Res. 2010, 183:183-208.
41. 2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. Bioorg. Med. Chem. Lett. 2007, 17:1376-1380.
42. Nimmerjahn A., et al. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
43. 2A receptor mediates microglial process retraction. Nat. Neurosci. 2009, 12:872-878.
44. Perry V.H., et al. The impact of systemic infection on the progression of neurodegenerative disease. Nat. Rev. Neurosci. 2003, 4:103-112.
45. Perry V.H., et al. Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol. 2007, 7:161-167.
46. Rinne J. Nigral degeneration in Parkinson's disease in relation to clinical features. Acta Neurol. Scand. 1991, 84:87-90.
47. Ross G.W., et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000, 283:2674-2679.
48. 12, a new platelet ADP receptor, target of clopidogrel. Biochem. Biophys. Res. Commun. 2001, 283:379-383.
49. 2A receptors in Parkinson's disease. Trends Neurosci. 2006, 29:647-654.
50. Seniuk N., et al. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 1990, 527:7-20.
51. 2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum. Brain Res. 2009, 1283:115-126.
52. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 2010, 37:510-518.
53. Tatton N., Kish S. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997, 77:1037-1048.
54. Walker F.R., et al. Dynamic structural remodelling of microglia in health and disease: a review of the models, signals and the mechanisms. Brain Behav. Immun. 2014, 37:1-14.
55. 2A receptors contribute to l-3,4-dihyrdoxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J. Neurosci. 2006, 26:13548-13555.
56. 2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann. Neurol. 2008, 63:338-346.
57. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedeberg's Arch. Pharmacol. 2000, 362:299-309.